Correcting neuromuscular pathogenic variants with CRISPR-Cas9 technology

被引：1

作者：

Best, H. ^{[1
]}

Woodman, K. ^{[1
]}

Lek, A. ^{[1
]}

Koczwara, K. ^{[1
]}

Xu, E. ^{[1
]}

Aykanat, A. ^{[2
]}

Jiang, Y. ^{[1
]}

Saltzman, M. ^{[1
]}

Beggs, A. ^{[2
]}

Lek, M. ^{[1
]}

机构：

[1] Yale Univ, New Haven, CT USA

[2] Harvard Med Sch, Boston, MA 02115 USA

来源：

关键词：

D O I：

10.1016/j.nmd.2019.06.025

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

O.7

引用

页码：S39 / S40

页数：2

共 50 条

[21] Engineering Genes with CRISPR-Cas9
Luo, Michelle L.
Beisel, Chase L.
[J]. CHEMICAL ENGINEERING PROGRESS, 2016, 112 (09) : 36 - 41
[22] CRISPR-Cas9: a world first?
不详
[J]. LANCET, 2018, 392 (10163): : 2413 - 2413
[23] Nanoparticles for CRISPR-Cas9 delivery
Glass, Zachary
Li, Yamin
Xu, Qiaobing
[J]. NATURE BIOMEDICAL ENGINEERING, 2017, 1 (11): : 854 - 855
[24] Protein Inhibitors of CRISPR-Cas9
Bondy-Denomy, Joseph
[J]. ACS CHEMICAL BIOLOGY, 2018, 13 (02) : 417 - 423
[25] CRISPR-Cas9 Structures and Mechanisms
Jiang, Fuguo
Doudna, Jennifer A.
[J]. ANNUAL REVIEW OF BIOPHYSICS, VOL 46, 2017, 46 : 505 - 529
[26] The invisible dance of CRISPR-Cas9
Palermo, Giulia
Ricci, Clarisse G.
McCammon, J. Andrew
[J]. PHYSICS TODAY, 2019, 72 (04) : 30 - 36
[27] CRISPR-Cas9 in cancer therapeutics
Randhawa, Shubhchintan
[J]. REPROGRAMMING THE GENOME: CRISPR-CAS-BASED HUMAN DISEASE THERAPY, 2021, 181 : 129 - 163
[28] MicroRNAs tame CRISPR-Cas9
Jouravleva, Karina
Zamore, Phillip D.
[J]. NATURE CELL BIOLOGY, 2019, 21 (04) : 416 - 417
[29] CRISPR-Cas9 wins Nobel
Strzyz, Paulina
[J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2020, 21 (12) : 714 - 714
[30] Allergan dives into CRISPR-Cas9
不详
[J]. NATURE BIOTECHNOLOGY, 2017, 35 (04) : 296 - 296